RTP Mobile Logo
Oncology Grand Rounds Series: Colorectal and Gastroesophageal Cancers (Webinar Audio Proceedings) — an NCPD-Accredited Program for Nurses
Released June 2021

Proceedings from the fourth in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Johanna Bendell and Daniel Catenacci on cases from the practice of Ms Jessica Mitchell. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal and gastroesophageal cancers.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with colorectal and gastroesophageal cancers.

    LEARNING OBJECTIVES

    • Educate patients with metastatic colorectal cancer (mCRC) regarding the importance of age, performance status, biomarker profile, primary tumor sidedness, prior systemic therapy, symptomatology and personal goals of treatment in the selection and sequencing of therapy.
    • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and understand how this regimen is being optimally incorporated into clinical care.
    • Assess the relevance of HER2 status, PD-L1 combined positive score, clinical factors and patient preferences in order to develop strategies to counsel individuals with locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer regarding personalized treatment recommendations.
    • Recognize the recent FDA approval of trastuzumab deruxtecan for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen, and discern how this agent can be optimally integrated into nonresearch care algorithms.
    • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy for gastric, esophageal or GEJ cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
    • Consider the recent FDA approval of pembrolizumab in combination with chemotherapy for patients with locally advanced or metastatic esophageal or GEJ carcinoma who are not candidates for surgical resection or definitive chemoradiation therapy.
    • Recall available and emerging data with investigational agents and strategies currently in clinical testing for colorectal, gastric, esophageal and GEJ cancers, and refer appropriate patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    Audio Program: This educational activity for 1.5 contact hours is provided by RTP during the period of June 2021 through June 2022.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1 contact hour is provided by RTP during the period of June 2021 through June 2022.

    This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSCRCGE2021/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCRCGE2021/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSCRCGE2021/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCRCGE2021/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSCRCGE2021.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Johanna Bendell, MD
    Chief Development Officer
    Director, Drug Development Unit Nashville
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements (to Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Fusion Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Relay Therapeutics, Repertoire Immune Medicines, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc; Contracted Research (to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, CALGB, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, Hutchison MediPharma, IGM Biosciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Morphotek Inc, Nektar, NeoImmuneTech, NGM Biopharmaceuticals, Novartis, NovoCure Inc, Numab, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, OncXerna Therapeutics Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, PureTech Health, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seagen Inc, Shattuck Labs, Sierra Oncology, Sumitomo Dainippon Pharma Oncology Inc, Stemcentrx, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Transcenta, Treadwell Therapeutics, Tyrogenex, Unum Therapeutics, Vyriad, Zymeworks.

    Daniel Catenacci, MD
    Associate Professor, Department of Medicine, Section of Hematology and Oncology
    Director, Interdisciplinary Gastrointestinal Oncology Program
    Assistant Director, Translational Research, Comprehensive Cancer Center
    The University of Chicago Medical Center and Biological Sciences
    Chicago, Illinois

    Advisory Committee: Astellas, Merck, Seagen Inc, Tempus; Consulting Agreements: Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group; Data and Safety Board: Genentech, a member of the Roche Group, Merck Serono; Speakers Bureau: Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus.

    Oncology Nurse Practitioner

    Jessica Mitchell, APRN, CNP, MPH
    Assistant Professor of Oncology
    Mayo Clinic College of Medicine and Science
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, TG Therapeutics Inc, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Lilly and Taiho Oncology Inc.

    Release date: June 2021
    Expiration date: June 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):